In vitro generation of procoagulant activity by Corynebacterium parvum-stimulated mononuclear leukocytes.
Thromboembolic complications are known in cancer patients after i.v. administration of Corynebacterium parvum. We examined the ability of this organism to induce production of procoagulant activity by human blood mononuclear leukocytes in vitro. After 4 hours incubation Corynebacterium parvum was an effective stimulant for mononuclear leukocytes, behaving in the same way as the typical gram-negative bacterium Escherichia coli, whereas mononuclear cells incubated with Staphylococcus aureus were not affected. Corynebacterium parvum used was found devoid of endotoxin by the Limulus assay and was not affected by Polymyxin B, which, on the contrary, inhibited Escherichia coli-induced production of procoagulant activity. Intact Corynebacterium parvum may be required for the production of procoagulant activity and, although this specific aspect of the research will require further study, from the exposed data it is concluded that such a production could be a factor contributing to the pathogenesis of the coagulopathy following Corynebacterium parvum therapy.
D001780:Blood Coagulation Tests; D004926:Escherichia coli / Q000276:immunology; D006801:Humans; D008033:Limulus Test; D009504:Neutrophils / Q000187:drug effects / Q000276:immunology*; D011112:Polymyxin B / Q000494:pharmacology; D011425:Propionibacterium acnes / Q000276:immunology*; D013211:Staphylococcus aureus / Q000276:immunology
D011112:Polymyxin B